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PACAP-38 induces neuronal differentiation of human SH-SY5Y
neuroblastoma cells via cAMP-mediated activation of ERK and
p38 MAP kinases
1
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The 38-amino acid pituitary adenylate cyclase (AC) activat-
ing polypeptide (PACAP) is an important neuropeptide and
neuroendocrine hormone that was ﬁrst isolated from ovine
hypothalamus extracts because of its potent ability to activate
AC (Miyata et al. 1989). There are several actions associated
with PACAP in both the developing and mature nervous
systems (reviewed by Vaudry et al. 2000). PACAP is a
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Abstract
The intracellular signaling pathways mediating the neuro-
trophic actions of pituitary adenylate cyclase-activating poly-
peptide (PACAP) were investigated in human neuroblastoma
SH-SY5Y cells. Previously, we showed that SH-SY5Y cells
express the PAC1 and VIP/PACAP receptor type 2 (VPAC2)
receptors, and that the robust cAMP production in response to
PACAP and vasoactive intestinal peptide (VIP) was mediated
by PAC1 receptors (Lutz et al. 2006). Here, we investigated
the ability of PACAP-38 to differentiate SH-SY5Y cells by
measuring morphological changes and the expression of
neuronal markers. PACAP-38 caused a concentration-
dependent increase in the number of neurite-bearing cells and
an up-regulation in the expression of the neuronal proteins
Bcl-2, growth-associated protein-43 (GAP-43) and choline
acetyltransferase: VIP was less effective than PACAP-38 and
the VPAC2 receptor-speciﬁc agonist, Ro 25-1553, had no
effect. The effects of PACAP-38 and VIP were blocked by the
PAC1 receptor antagonist, PACAP6-38. As observed with
PACAP-38, the adenylyl cyclase activator, forskolin, also in-
duced an increase in the number of neurite-bearing cells and
an up-regulation in the expression of Bcl-2 and GAP-43.
PACAP-induced differentiation was prevented by the adenylyl
cyclase inhibitor, 2¢,5¢-dideoxyadenosine (DDA), but not the
protein kinase A (PKA) inhibitor, H89, or by siRNA-mediated
knock-down of the PKA catalytic subunit. PACAP-38 and
forskolin stimulated the activation of extracellular signal-
regulated kinase (ERK), mitogen-activated protein kinase
(MAP; p38 MAP kinase) and c-Jun N-terminal kinase (JNK).
PACAP-induced neuritogenesis was blocked by the MEK1
inhibitor PD98059 and partially by the p38 MAP kinase
inhibitor SB203580. Activation of exchange protein directly
activated by cAMP (Epac) partially mimicked the effects of
PACAP-38, and led to the phosphorylation of ERK but not p38
MAP kinase. These results provide evidence that the neuro-
trophic effects of PACAP-38 on human SH-SY5Y neuroblas-
toma cells are mediated by the PAC1 receptor through a
cAMP-dependent but PKA-independent mechanism, and fur-
thermore suggest that this involves Epac-dependent activa-
tion of ERK as well as activation of the p38 MAP kinase
signaling pathway.
Keywords: cAMP-dependent, Epac, neuritogenesis, PAC1
receptor, PACAP, VIP.
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  2007 The Authorswell-documented neurotrophic factor, regulating neuronal
survival, neurotransmitter phenotype, axon growth and
growth cone attraction (DiCicco-Bloom and Deutsch 1992;
Gonzalez et al. 1997; Villalba et al. 1997; Vaudry et al.
1999; Borba et al. 2005; Dejda et al. 2005; Falluel-Morel
et al. 2005). In the mature nervous system, PACAP has been
shown to act as a neurotransmitter and neuromodulator and
has also been shown to increase cell survival after neuronal
trauma (Harrington et al. 1999; Inoue et al. 2000; Onoue
et al. 2002; Farkas et al. 2004; Tamas et al. 2006). PACAP
expression is up-regulated at sites of neuronal injury (Zhang
et al. 1995, 1996; Moller et al. 1997; Boeshore et al. 2004)
where it may help prevent cell death and promote neuronal
regeneration.
The actions of PACAP are mediated through three G
protein-coupled receptors (GPCRs), the VPAC1,V P A C 2,
and PAC1 receptors (Zhou et al. 2002), which are
members of the Group II secretin receptor family (Harmar
2001). PACAP and the structurally related neuropeptide,
vasoactive intestinal peptide (VIP), have similar potencies
at the VPAC receptors (Laburthe et al. 2002), whereas
PACAP is ‡100-fold more potent than VIP at the PAC1
receptor (Lutz et al. 2006). Similar to other Group II
GPCRs, the VPAC and PAC1 receptors couple to the
activation of AC (Harmar and Lutz 1994). In addition,
VPAC and PAC1 receptors differentially couple to the
activation of phospholipase C and phospholipase D
(Spengler et al. 1993; Langer et al. 2001; MacKenzie
et al. 2001; McCulloch et al. 2001).
Although PACAP has long been known to be involved
in neuronal development and regeneration, very little is
known about the signal transduction pathways which
mediate the neurotrophic effects of PACAP on human
neuronal cells. The human neuroblastoma cell line SH-
SY5Y is a well-characterized model for neuronal differen-
tiation (Pa ˚hlman et al. 1990). These cells have been shown
to respond to various differentiation factors, such as
retinoic acid (RA), staurosporine, or brain-derived neuro-
trophic factor by an increase in neurite outgrowths and
up-regulation of the expression of markers of neuronal
differentiation including Bcl-2 and GAP-43 (Leli et al.
1992; Hanada et al. 1993; Encinas et al. 1999; Feng and
Porter 1999; Jamsa et al. 2004; Pan et al. 2005). Recently,
it has been shown that PACAP induces neurite outgrowths
and increased expression of neuronal cytoskeletal proteins
in SH-SY5Y cells (He ´raud et al. 2004), however, the
signal transduction mechanisms underlying this were not
determined. We have shown previously that SH-SY5Y
cells express PAC1 and VPAC2 receptors and that PAC1
receptors mediate the activation of cAMP production in
these cells by PACAP and VIP (Lutz et al. 2006). Here
we have investigated PAC1 receptor-mediated activation of
cAMP production in promoting the differentiation of SH-
SY5Y cells by PACAP.
Materials and methods
Materials
Tissue culture media were obtained from Sigma–Aldrich (Poole,
UK), and animal sera from Biowest Ltd. (Ringmer, UK). The
SH-SY5Y cell line was obtained from ECACC (Salisbury, UK).
Peptides, all-trans retinoic acid, phorbol-12-myristate-13-acetate
(PMA) and enzyme inhibitors were supplied by Merck Bio-
sciences (UK) Ltd. (Nottingham, UK), except for PD98059 which
was obtained from Promega (Southampton, UK). The selective
VPAC2 receptor agonist, Ro 25-1553, was obtained from Dr.
Patrick Robberecht, Universite ´ Libre de Bruxelles, Brussels,
Belgium. The exchange protein directly activated by cAMP
(Epac) activator, 8-(4-chlorophenylthio)-2¢O-methyladenosine
3¢,5¢-cyclic monophosphate sodium salt was obtained from
Sigma–Aldrich. Antibodies against Bcl-2, ERK, phosphoERK,
GAP-43, tyrosine hydroxylase (TH) and GAPDH were obtained
from Santa Cruz Biotechnology (Autogen Bioclear UK Ltd.,
Calne, UK), all other antibodies were obtained from Biosource
(Paisley, UK). Standard laboratory chemicals of Analar grade
were obtained from Sigma–Aldrich or BDH Chemicals Ltd.
(Poole, UK).
Cell culture
SH-SY5Y cells were maintained at 37 C in a humidiﬁed
atmosphere of 5% CO2 and 95% air and cultured in a 1 : 1
mixture of Ham’s F12 and Eagle’s minimum essential medium
supplemented with non-essential amino acids, L-glutamine,
sodium pyruvate, 100 U/mL each of penicillin and streptomycin,
and 5% fetal bovine serum (FBS). Medium was changed every
fourth day. All the cells used in this study were used at a low
passage number (<20).
cAMP assay
The production of cAMP was measured by the b-galactosidase
enzyme fragment complementation-based HitHunter cAMP XS+
chemiluminesence assay (DiscoveRx, Birmingham, UK) according
to the manufacturer’s instructions. Brieﬂy, SH-SY5Y cells at 80%
conﬂuency in 75 cm
2 ﬂasks were quiesced for 2 h in OptiMEM
(Invitrogen Ltd., Paisley, UK) before being scraped into phosphate-
buffered saline and counted. Cells were centrifuged at 400 g for
5 mins and resuspended in MEM containing 0.25% bovine serum
albumin (BSA; Sigma-Aldrich) and 500 lmol/L 3-isobutyl-
1-methylxanthine for 15 min. Cells were assayed in suspension by
putting 10
4 cells per well into a 96-well plate before stimulating with
varying concentrations of ligand. The assay was stopped after
15 min by lysing cells and luminescence was detected using a
LUMIstar Galaxy plate reader (BMG Labtech Ltd., Aylesbury,
Bucks, UK). In addition, SH-SY5Y cells plated into 24-well plates
were pre-labeled overnight with [
3H]-adenine and [
3H]cAMP
production measured as described by [Wong, 1994 #36]. [
3H]ATP/
ADP and [
3H]cAMP were isolated from each sample by sequential
chromatography on anion exchange and alumina columns and the
amount of radioactivity of the ﬂow through (representing
[
3H]ATP+[
3H]ADP) and eluate (representing [
3H]cAMP) measured
by scintillation counting. The levels of cAMP production
were calculated as the ratio of [[
3H]cAMP]/([[
3H]cAMP] +
[[
3H]ATP+[
3H]ADP]).
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SH-SY5Y cells were seeded into 12-well plates at a density of
3 · 10
6 cells per well and cultured for 48 h, after which the medium
was replaced with low-serum medium containing 0.2% FBS and
incubated overnight. Medium was replaced with fresh low-serum
medium for 2 h before agonists were added, inhibitors were added
45 min before adding agonists. Stimulation was halted by placing
plates on ice and cells harvested by preparing whole cell extracts on
ice after aspirating the medium and adding lysis buffer (250 mmol/L
Tris, pH 6.8, 14 mmol/L sodium pyrophosphate, 20 mmol/L
ethylenediaminetetraacetic acid (EDTA), 35 mmol/L sodium dode-
cyl sulphate as described previously (McLees et al. 1995). Cells
scraped into lysis buffer were homogenized by passing through a
21G needle and protein concentration quantiﬁed using a standard
Coomassie-based Bradford assay.
Differentiation of SH-SY5Y cells
SH-SY5Y cells were plated into 12-well plates at a density of 10
5
cells per well and cultured for 48 h. Before starting treatments, the
cells were incubated for 16–24 h in low-serum medium containing
0.2% FBS, then photographed under a 40· objective lens using a
Nikon Coolpix 4500 camera attached to an Olympus CK40
microscope (Microscopes Scales & Servicing, Glasgow, UK).
Medium was replaced with fresh low-serum medium and treatments
added. Where indicated, inhibitors were added 45 min before the
treatment. Micrographs were taken 48 h after the initial treatment
and medium-containing treatments were renewed; this was repeated
every 48 h for up to 8 days. Cells were harvested as described above.
Cell morphology analysis
Cell morphology analysis was carried out on captured micrographs
of treated cells. For each treatment, the total number of cells and
total number of cells with neurites longer than the length of the cell
body were manually assessed from at least six micrographs in a
blind count. The ratio between the number of neurite-bearing cells
and total number of cells was calculated for each treatment, and the
fold change over the control was determined. Each experiment was
repeated a minimum of three times and variance between datasets
determined by ANOVA analysis using GraphPad Prism (GraphPad
Software, Inc., San Diego CA, USA). Adobe Photoshop was used to
adjust the contrast of the micrograph images.
SDS–PAGE and western blots
Whole cell extracts were mixed with an equal volume of 2X
standard Laemmli buffer, containing 100 mmol/L dithiothreitol, and
denatured at 100 C for 5 min. 20 lg of protein was then separated
on a 10% sodium dodecyl sulphate–polyacrylamide gel electropho-
resis gel and transferred onto Hybond ECL  nitrocellulose
membrane (GE Healthcare, Chalfont St Giles, UK). Membranes
were blocked for 2 h at 17 C with 2% BSA in Tris-buffered saline/
0.03% Tween-20 (TBST), then incubated overnight with primary
antibody as indicated, diluted in TBST containing 0.2% BSA.
Following several washes in TBST, membranes were incubated
with horseradish peroxidase-conjugated secondary antibody (GE
Healthcare) and detected by enhanced chemiluminescence using a
Fuji LAS-3000 imager (Raytek Scientiﬁc Ltd., Shefﬁeld, UK).
Western blots were quantiﬁed using Kodak 1D Image Analysis
software and given as a ratio of net intensity/band area (pixels).
siRNA knock-down
Expression of the protein kinase A catalytic subunit (PKAc) was
inhibited using the SignalSilence PKAc siRNA kit (Cell Signalling
Technology, Hitchin, Hertfordshire, UK) used according to the
manufacturer’s instructions. Brieﬂy, 10
5 cells were transfected with
30 pmoles siRNA oligonucleotide and incubated for 48 h before
treatment. Knock-down of PKAc was assessed by western blotting
and speciﬁcity of RNA interference determined by western blotting
for the related protein, protein kinase B.
Immunocytochemistry
Cells were plated at a density of 10
4 cells per well onto ﬁbronectin-
coated coverslips in 12-well plates and incubated for 48 h. Cells
were washed in ice-cold tris-bufferd saline (TBS) and ﬁxed at
)20 C in methanol for 10 min before incubating with primary
antibody diluted in TBS/1% BSA, as indicated, overnight at 4 C.
After several washes in TBS, cells were probed with AlexaFluor
conjugated secondary antibody (Invitrogen) and mounted on to
slides using Moviol (65 lmol/L polyvinyl alcohol, 80 mmol/L Tris.
pH 8.5, 2.5% 1,4-diazobicyclooctane, 17% glycerol). Cells were
examined with a Nikon ﬂuorescent microscope and image analysis
carried out using the IP Labs 3.7 software (Nikon UK Ltd., Surrey,
UK).
Data analysis
Curve ﬁtting was accomplished using GraphPad Prism (GraphPad
Software, Inc., San Diego CA, USA). The data are expressed as
mean ± standard error (SE). One- and two-way ANOVA were carried
out as appropriate to identify signiﬁcant differences between
treatments.
Results
PACAP-38 induces neuritogenesis and the expression of
neuronal marker proteins in SH-SY5Y cells
Cells maintained in medium containing 0.2% FBS (low
serum medium) were treated with different concentrations of
PACAP-38 (0.1 nmol/L to 1 lmol/L) and examined for
changes in cell morphology and expression of neuronal
differentiation-associated proteins. The number of neurite-
bearing cells increased within 2 days of treatment: those
treated with 10 nmol/L to 1 lmol/L PACAP-38 displayed a
bipolar cell body with long, thin, neurite-like processes by
day 4 (Fig. 1a). Cells treated with 10 lmol/L RA also
developed long, thin, neurite extensions (Fig. 1a), as shown
in previous studies (Pa ˚hlman et al. 1984), whereas control
cells treated with dimethylformamide (vehicle) or maintained
in low serum medium alone did not. Since SH-SY5Y cells
express PAC1 receptor splice variants that are responsive to
VIP, as well as the VIP/PACAP-responsive VPAC2 receptors
(Lutz et al. 2006), the effects of VIP and the VPAC2
receptor-speciﬁc agonist, Ro 25-1553, were tested. VIP was
also able to induce the development of neurite-like processes,
but required 100-fold higher concentrations than PACAP-38
Journal Compilation   2007 International Society for Neurochemistry, J. Neurochem. (2008) 104, 74–88
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(10 lmol/L) elicited the development of neurites in a small
proportion of cells. Figure 1b shows the increase in neurite-
bearing cells on day 4 in response to PACAP-38, VIP, and Ro
25-1553. A concentration-dependent increase was observed,
with 100 nmol/L PACAP-38 eliciting the greatest increase
(5.6 ± 0.5-fold), compared to 1 lmol/L VIP (3.2 ± 0.4-fold)
and 10 lmol/L Ro 25-1553 (2.1 ± 0.3-fold). The number of
neurite-bearing cells increased by 8.3 ± 1.3-fold (p < 0.001)
following 4 day treatment with 10 lmol/L RA.
The effects of various concentrations of PACAP-38, VIP,
and Ro 25-1553 on the expression of Bcl-2 and GAP-43
were assessed by western blotting (Fig. 1c). Protein loading
for each sample was checked by blotting for the housekeep-
ing gene glyceraldehyde-3-phosphate dehydrogenase (GAP-
DH). Low concentrations of PACAP-38 were found to
increase the expression of Bcl-2 and GAP-43 (0.1 nmol/L
and 1 nmol/L, respectively). In comparison, much higher
concentrations of VIP were needed to induce expression of
these two markers of neuronal differentiation (approximately
10 nmol/L and 1 lmol/L, respectively, Fig. 1c), whereas Ro
25-1553 was even less potent. In addition, the ability of
PACAP-38 to affect the neurotransmitter phenotype was
determined by examining the expression of choline acetyl-
transferase (ChAT), a marker for cholinergic neurones, and
tyrosine hydroxylase (TH), a marker for noradrenergic
neurones. SH-SY5Y cells normally express TH, and the
levels of TH were not signiﬁcantly affected by the 4-day
treatment of cells with the varying concentrations of PACAP-
38 used in this study (Fig. 1c). However, treatment of SH-
SY5Y cells with 1 nmol/L PACAP-38 was sufﬁcient to
induce expression of ChAT, the level of expression increas-
ing in a concentration-dependent manner. (Fig. 1c).
PACAP6-38 inhibits PACAP-38-induced neuronal
differentiation of SH-SY5Y cells
The PAC1 receptor antagonist PACAP6-38 was used in order
to determine if PAC1 receptors are involved in mediating the
Fig. 1 The effect of PACAP on differentia-
tion of SH-SY5Y cells. SH-SY5Y cells were
cultured in low serum medium for 24 h be-
fore being incubated with increasing con-
centrations of PACAP-38 (PACAP), retinoic
acid (RA), VIP, Ro 25-1553 or dimethylfor-
mamide, as indicated. Medium and treat-
ments were replaced after 2 days and
micrographs captured after 4 days (a).
Micrographs are set to the same scale; the
scale bar represents 50 lm. (b) The total
number of cells, and the number of cells
bearing neurites greater than the length of
the cell body were counted and the data
expressed as fold of basal control. Experi-
ments were performed in triplicate and
one- and two-way ANOVA carried out to
determine differences between treatments
(***p < 0.001). (c) After capture of micro-
graphs, whole cell extracts were taken and
the proteins separated and blotted as
detailed in Materials and methods. Anti-
bodies speciﬁc for Bcl-2, GAP-43, ChAT,
TH and GAPDH were used as indicated.
Cell extracts from cells treated with
100 nmol/L PACAP-38 (P-38) were run
alongside those from cells treated with VIP
and Ro 25-1553 at the indicated con-
centrations for comparison. Each blot is
representative of three independent exper-
iments.
  2007 The Authors
Journal Compilation   2007 International Society for Neurochemistry, J. Neurochem. (2008) 104, 74–88
PACAP-mediated neurodifferentiation of human SH-SY5Y cells | 77differentiating effects of PACAP-38 on SH-SY5Y cells. This
inhibitor has also been shown to act at VPAC2 receptors
(Dickinson et al. 1997; Moro et al. 1999), however, since Ro
25-1553 did not have a signiﬁcant effect on neuritogenesis or
the expression of Bcl-2 and GAP-43, it seems unlikely that
the VPAC2 receptor has a signiﬁcant role in mediating
PACAP-38-induced neuronal differentiation of SH-SY5Y
cells. The ability of PACAP6-38 to inhibit PACAP-38-, VIP-
and Ro 25-1553-stimulated cAMP production was tested in
SH-SY5Y cells. Fig. 2a shows that the inhibitor had no effect
on basal levels of cAMP, but signiﬁcantly inhibited
100 nmol/L PACAP-38- and 1 lmol/L VIP-stimulated
cAMP production by 81 ± 25% and 85 ± 26%, respectively.
Likewise, 4-day treatment with 10 lmol/L PACAP6-38 did
not signiﬁcantly alter the basal number of neurite-bearing
cells whereas the 100 nmol/L PACAP-38- or 1 lmol/L VIP-
stimulated increase in the number of neurite-bearing cells
was signiﬁcantly reduced, by 78 ± 23% and 77 ± 22%,
respectively, following co-treatment with 10 lmol/L PA-
CAP6-38 (Fig. 2b). PACAP-38-induced expression of Bcl-2
and GAP-43 was also inhibited by 10 lmol/L PACAP6-38
(Fig. 2c). Thus, it appears likely that this is mediated
principally through the PAC1 receptor.
Production of cAMP is required for PACAP-38-induced
neuronal differentiation of SH-SY5Y cells
Treatment of SH-SY5Y cells with cAMP analogues has been
shown to induce differentiation (Sa ´nchez et al. 2004). Since
PACAP elicits a robust activation of cAMP production in
SH-SY5Y cells through the PAC1 receptor (Lutz et al. 2006),
the AC inhibitor, DDA, was used in this study to determine if
PACAP-38-induced differentiation of SH-SY5Y cells was
cAMP-dependent. In SH-SY5Y cells 300 lmol/L DDA
inhibited 100 nmol/L PACAP-38-stimulated cAMP produc-
tion to 25 ± 19% of the PACAP-38-stimulated control
(n = 3), DDA was calculated to have an IC50 of
208 ± 0.3 nmol/L (n = 3: data not shown). The AC activa-
tor, forskolin, was used for comparison to PACAP-38.
Forskolin elicits cAMP production with an EC50 of
5.8 ± 0.2 lmol/L and Emax of 12 ± 1-fold of basal control
in SH-SY5Y cells (data not shown). Cells were then
maintained in: low serum medium; 300 lmol/L DDA;
100 nmol/L PACAP-38; 300 lmol/L DDA and 100 nmol/L
PACAP-38; 10 lmol/L forskolin. Changes in cell morphol-
ogy and expression of Bcl-2 and GAP-43 were examined
after 4 days of treatment. As shown in Fig. 3a, treatment
with DDA alone had no effect compared to control cells but
inhibits the PACAP-38-induced increase in neurite-bearing
cells by approximately 76 ± 36%. Furthermore, DDA had no
effect on basal levels of Bcl-2 and GAP-43 expression
compared to control cells, but caused a near complete
inhibition of their induction by 100 nmol/L PACAP-38
(Fig. 3b). Four day treatment of SH-SY5Y cells maintained
in low serum medium with 10 lmol/L forskolin caused an
Fig. 2 The effects ofthe PAC1 receptorantagonist PACAP6-38 on SH-
SY5Y cells. SH-SY5Y cells were maintained in low serum medium as
describedinMaterialsandmethods.(a)Histogramshowingfoldchange
in cAMP levels for cells treated for 15 min with 100 nmol/L PACAP-38,
1 lM VIP or 1 lM Ro 25-1553, in the presence (dark gray bars), or
absence (light gray bars) of 10 lM PACAP6-38. The basal level was
determined for cells maintained in low serum medium alone. (b) Histo-
gram showing numbers of neurite-bearing cells (fold of basal control)
following treatment for 4 days with 100 nmol/L PACAP-38, 1 lM VIP or
1 lMRo25-1553,inthepresence(darkgraybars)orabsence(lightgray
bars) of 10 lM PACAP6-38. Standard error bars are shown (n = 3) and
one-way ANOVA performed to identify signiﬁcant differences between
treatments (***p < 0.001, **p < 0.01, *p < 0.05). (c) Western blot
analysis of cell extracts using antibodies speciﬁc for Bcl-2 and GAP-43
was carried out following the different treatments for 4 days. Protein
loading was determined using an antibody speciﬁc for GAPDH.
Each blot represents three independent experiments. (C = control,
p = 100 nmol/L PACAP-38, V = 1 lM VIP, R = 1 lmol/L Ro 25-1553).
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fold of basal control (Fig. 3a) and induced the expression of
Bcl-2 and GAP-43 (Fig. 3b).
Protein kinase A is not required for PACAP-38-induced
neuritogenesis
As protein kinase A (PKA) is one of the major intracellular
effectors activated by elevated levels of cAMP, we set out to
determine if PKA is required for PACAP-38-mediated
differentiation of SH-SY5Y cells. The transcription factor
cAMP response element binding protein (CREB) is a
downstream target of PKA and was used in this study as a
measure of PACAP-38-mediated PKA activation and
the effectiveness of PKA inhibitors. Concentrations of
PACAP-38 as low as 0.1 nmol/L elicited an increase in
pCREB over basal levels (Fig. 4a, upper left panel). For cells
treated with 100 nmol/L PACAP-38, pCREB levels were
elevated within 5 min and remained elevated for at least
60 min (right panel, Fig. 4a). PACAP-38-stimulated CREB
phosphorylation was inhibited by treating cells with the PKA
inhibitor H89 at concentrations of 1, 10, and 100 lmol/L
(Fig. 4b). Interestingly, treatment of cells with 10 lmol/L
H89 in low serum medium for 4 days elicited a signiﬁcant
increase in the number of neurite-bearing cells to 3.5 ± 0.3-
fold of basal control and augmented the 100 nmol/L PACAP-
38-induced increase (Fig. 4b, right panel), although this
augmentation was not signiﬁcant compared to PACAP-38
alone. The PACAP-38-induced expression of Bcl-2 was
partially inhibited by 10 lmol/L H89, however, that of GAP-
43 was not affected (Fig. 4b, lower left panel).
Although H89 is widely used as a speciﬁc PKA inhibitor,
it has been shown to potently inhibit other kinases including
Rho kinase/ROCK-II (Davies et al. 2000). Inhibition of this
kinase rather than PKA by H89 has been shown to lead to the
formation of neurite-like extensions in NG108-15 cells
(Leemhuis et al. 2002). In order to explore further the role
of PKA in PACAP-38-induced neurite extensions in SH-
SY5Y cells, siRNA was used to knock-down expression of
the PKA catalytic subunit. The effectiveness and speciﬁcity
of this is shown in the top panel of Fig. 4c, where expression
of the catalytic subunit of PKA is decreased by treatment
with PKAc siRNA, but not with the scrambled siRNA
sequence (ss). Expression of the closely related protein
kinase B (second panel, Fig. 4c) is not affected by either
treatment. Down-regulation of PKAc by siRNA effectively
inhibits the increase in pCREB levels in cells treated with
100 nmol/L PACAP-38 (third panel, Fig. 4c), but only
partially reduces PACAP-38-induced Bcl-2 expression and
does not affect that of GAP-43 (bottom panels, Fig. 4c), as
we have observed following H89 treatment (Fig. 4b).
However, down-regulation of PKAc had no signiﬁcant effect
on the formation of neurite extensions compared to controls,
and did not augment 100 nmol/L PACAP-38-induced
increase in neurite-bearing cells compared to control cells
(graph, Fig. 4c), as found with H89. Taken together, these
results suggest that PKA activity is required for PACAP-38-
induced expression of Bcl-2, but not for GAP-43 or for
PACAP-38-induced neuritogenesis. Furthermore, they sug-
gest that H89 may be inhibiting another protein kinase in
addition to PKA in SH-SY5Y cells, as observed in NG108-
15 cells (Leemhuis et al. 2002). The identity of this kinase
remains to be established.
PACAP-38-induced neuronal differentiation of SH-SY5Y
cells is dependent upon ERK and p38 MAP kinase activity
The MAP kinase signaling pathways have a well-docu-
mented role in cell proliferation and differentiation. Here,
activation of the MAP kinase signaling pathways by
Fig. 3 The effects of DDA and Forskolin on differentiation of SH-SY5Y
cells. SH-SY5Y cells were maintained in low serum medium as pre-
viously described. (a) Histogram showing for the numbers of neurite-
bearing cells following treatment with 100 nmol/L PACAP-38 in the
presence or absence of 300 lmol/L DDA, or for cells treated with
10 lmol/L forskolin for 4 days. Standard error bars are shown (n = 3),
one-way ANOVA analysis was carried out to identify signiﬁcant dif-
ferences between treatments (**p < 0.01). (b) Western blot analysis of
cell extracts using antibodies speciﬁc for Bcl-2 and GAP-43 was car-
ried out following the different treatments for 4 days. Protein loading
was determined using an antibody speciﬁc for GAPDH. Each blot
represents three independent experiments.
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Cells maintained in low serum medium were stimulated
for 15 min with a concentration range of 0.1 nmol/L to
1 lmol/L PACAP-38, and phosphorylation of ERK 1 and
2, p38 MAP kinase and JNK were assessed by western
blotting using speciﬁc antibodies (Fig. 5). PACAP-38
stimulated phosphorylation of ERK (pERK), p38 MAP
kinase (p-p38 MAP kinase) and JNK (pJNK) in a
concentration-dependent manner (Fig. 5a), with EC50 val-
ues of 0.7 nmol/L, 1.5 nmol/L and 37.7 nmol/L, respec-
tively. The pERK and p-p38 MAP kinase levels reached a
maximum at 10–100 nmol/L PACAP-38, a similar con-
Fig. 4 The effects of PKA inhibition on differentiation of SH-SY5Y
cells. SH-SY5Y cells were maintained in low serum medium as pre-
viously described. (a) Western blots showing changes in CREB
phosphorylation following a 15 min. treatment with increasing con-
centrations of PACAP-38 (left panel) and a time course of 100 nmol/L
PACAP-38-induced CREB phosphorylation (right panel). The total
CREB protein in each sample is shown in the lower panels. (b) The
effects of treating cells with H89 were assessed by Western blot
analysis of pCREB levels in whole cell extracts from cells treated with
1, 10 and 100 lmol/L H89 in the presence or absence of 100 nmol/L
PACAP-38 for 15 min (upper panel). The levels of total CREB protein
were also assessed for each sample. The effect of 10 lmol/L H89 on
levels of Bcl-2 and GAP-43 protein expression in cells in the presence
or absence of 100 nmol/L PACAP-38 for 4 days are shown in the
lower panels. The right panel is a histogram showing numbers of
neurite-bearing cells (fold of basal control) following treatment with
10 lmol/L H-89, in the presence (dark gray bars) or absence (light
gray bars) of 100 nmol/L PACAP-38. (c) Western blots showing
changes in expression of PKAc and PKB 2 days after siRNA trans-
fection to knock-down PKAc expression, and its affect on 100 nmol/L
PACAP-38-induced CREB (C = control, SS = scrambled siRNA se-
quence, PKAc siRNA = speciﬁc siRNA sequence targeting the cata-
lytic subunit of PKA). The right panel is a histogram showing numbers
of neurite-bearing cells (fold of basal control) following siRNA trans-
fection to knock-down PKAc expression, in the presence (dark gray
bars) or absence (light gray bars) of 100 nmol/L PACAP-38. ANOVA
analysis was performed to identify signiﬁcant differences between
treatments (***p < 0.001, **p < 0.01). Protein loading in (b) and (c)
was determined using an antibody speciﬁc for GAPDH. Each blot is
representative of three independent experiments.
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differentiated phenotype. The increase in pJNK was more
modest and required 10-fold greater concentration of
PACAP-38 to reach a maximal level, compared to the
other MAP kinases. Cells treated with 100 nmol/L
PACAP-38 displayed prolonged phosphorylation of ERK
and p38 MAP kinase (Fig. 5b) with pERK becoming
localized in the nucleus after 30 min of stimulation
(Fig. 5c). This is an event believed to switch ERK activity
from that mediating proliferation to that inducing differ-
entiation (Traverse et al. 1992; Ebisuya et al. 2005).
Although the levels of pERK declined almost back to
basal levels over the 2 h time course of the experiment,
the levels of p-p38 MAP kinase remained elevated
Fig. 5 PACAP-38-mediated activation of ERK, p38 MAP kinase and
JNK. SH-SY5Y cells were cultured in low serum medium for 24 h and
incubated with increasing concentrations of PACAP-38 for 15 min (a)
or with 100 nmol/L PACAP-38 for up to 2 h (b). Western blot analysis
of whole cell extracts was carried out using antibodies speciﬁc for
ERK, pERK, p-p38 MAP kinase and pJNK. The increase in phos-
phorylation levels was determined by densitometry as described in
Materials and methods and is graphically represented in the lower
section of the ﬁgure. Standard error bars are shown (n = 5). (c) The
cells were incubated with a pERK-speciﬁc antibody and its respective
ﬂuorescent dye-conjugated secondary antibody (green) following
treatment with 100 nmol/L PACAP-38 for 30 min. Cells were also
stained with DAPI, the DNA-binding ﬂuorescent stain (blue). Each
micrograph is representative of three independent experiments.
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declined quickly in comparison.
Because of the strength and duration of PACAP-elicited
phosphorylation of ERK and p38 MAP kinase, the involve-
ment of these kinase pathways in PACAP-38-induced cell
differentiation was examined. SH-SY5Y cells were main-
tained in low serum medium for 4 days with 10 lmol/L
PD98059 (an inhibitor of MEK1), with 10 lmol/L
SB203580 (an inhibitor of p38 MAP kinase) or in low
serum medium alone as the control, with or without
100 nmol/L PACAP-38. Changes in cell morphology and
expression of Bcl-2 and GAP-43 were determined. As shown
in Fig. 6a, inhibition of the ERK pathway caused a
signiﬁcant reduction in the number of neurite-bearing cells
induced by PACAP-38, from 4.6 ± 0.6-fold to 1.4 ± 0.4-fold
of basal control, an inhibition of approximately 85% of the
stimulated response. Inhibition of p38 MAP kinase pathway
caused a more modest reduction in the number of neurite-
bearing cells to 2.8 ± 0.4-fold of the basal control, an
inhibition of approximately 58% of the stimulated response.
The PACAP-induced increase in Bcl-2 levels was inhibited
by SB203580 and not by PD98059 whereas the converse was
true for GAP-43 (Fig. 6b).
The relationship between AC activation and MAP kinase
activation was explored by incubating cells with 300 lmol/L
DDA or low serum medium alone and stimulating with
100 nmol/L PACAP-38. The effects on the levels of
phosphorylated MAP kinase following treatment with
10 lmol/L forskolin were examined as well. As shown in
Fig. 6c, DDA inhibited the PACAP-38-stimulated increase in
pERK and p-p38 MAP kinase. Forskolin, like PACAP-38,
stimulates an increase in pERK and p-p38 MAP kinase. This
was not prevented by inhibiting PKA, as neither H89
(Fig. 6d) nor siRNA-mediated knock-down of the catalytic
subunit of PKA prevented the PACAP-38-induced increase
in pERK and p-p38 MAP kinase levels (Fig. 6e).
The Epac activator 8-CPT-Me-cAMP stimulates ERK but
not p38 MAP kinase activity
The PACAP-38-stimulated activation of ERK and p38 MAP
kinase is cAMP-dependent but PKA-independent in SH-
SY5Y cells. The guanine nucleotide exchange factor, Epac,
is also known to mediate cAMP-dependent activation of
MAP kinase in certain cell types, including PC6 cells (Shi
et al. 2006). We have examined this possibility here.
Figure 7a shows the effect of the speciﬁc Epac activator,
8-CPT-Me-cAMP, PACAP-38 and forskolin on pERK and
p-p38 MAP kinase levels. 8-CPT-Me-cAMP stimulated an
increase in pERK but not p-p38 MAP kinase. The time
course of this activation of ERK was examined and
Fig. 6 The effect of ERK and p38 MAP kinase on PACAP-induced
differentiation of SH-SY5Y cells. (a–b) SH-SY5Y cells were cultured in
low serum medium for 24 h and incubated with 10 lmol/L PD98059
(PD) or 10 lmol/L SB203580 (SB) for 45 min before treatment with
100 nmol/L PACAP-38 or low serum medium as control for 4 days.
Treatments were replaced after the second day. (a) The fold increase
in neurite-bearing cells was determined as described in Materials and
methods. Standard error bars are shown (n = 3) and ANOVA was
carried out to identify signiﬁcant differences between treatments
(***p < 0.001). (b) Western blot analysis of whole cell extracts using
antibodies speciﬁc for Bcl-2 and GAP-43 was carried out on day 4.
Protein loading was determined using an antibody speciﬁc for GAPDH.
(c-e) Western blot analysis of whole cell extracts was carried out using
antibodies speciﬁc for ERK, pERK and p-p38 MAP kinase. (c) Cells
cultured in low serum medium for 24 h were incubated with 300 lmol/
L DDA in the presence, or absence, of 100 nmol/L PACAP-38 or
10 lmol/L forskolin for 15 min. (d) Cells maintained in low serum
medium for 24 h were treated with 0.1, 1 and 10 lmol/L H89 for
45 min, then with or without 100 nmol/L PACAP-38 for 15 min. (e)
Expression of PKAc was inhibited by siRNA knock-down as described
in Materials and methods (C = control, SS = scrambled siRNA se-
quence, PKAc siRNA = speciﬁc siRNA sequence targeting the cata-
lytic subunit of PKA). Cells were incubated in the presence, or
absence, of 100 nmol/L PACAP-38 for 15 minutes. Each blot is rep-
resentative of three independent experiments.
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treated with 100 lmol/L 8-CPT-Me-cAMP had similar levels
of pERK to those treated with PACAP-38 within 30 min, but
the levels declined more slowly than the PACAP-38-
stimulated levels. However, 100 lmol/L 8-CPT-Me-cAMP
elicited an increase in the number of neurite-bearing cells to
2.2 ± 0.9-fold of basal control compared to 5.8 ± 1.3-fold
following treatment with 100 nmol/L PACAP-38 (Fig. 7c).
Expression of GAP-43 but not Bcl-2 was up-regulated by
100 lmol/L 8-CPT-Me-cAMP (Fig. 7d).
Discussion
Human SH-SY5Y cells differentiate into a more neuronal
phenotype when treated with the differentiating factors RA,
PMA, or brain-derived neurotrophic factor (Leli et al. 1992;
Jamsa et al. 2004; Pan et al. 2005) and we have used these
cells to explore the mechanisms involved in the neurotrophic
actions of PACAP. This is the ﬁrst study, to our knowledge,
to examine the signaling pathways underlying PACAP-38-
stimulated neuritogenesis in human cells. PACAP treatment
of SH-SY5Y cells elicited a large increase in the number of
neurite-bearing cells, corresponding to the formation of
neurons during development and to their regeneration after
injury. A number of studies have now identiﬁed PACAP as
having a role in increasing axon growth and preventing cell
death following: facial injury (Suarez et al. 2006); spinal
cord injury (Kim et al. 2000); traumatic brain injury (Farkas
et al. 2004); ischemia (Chen et al. 2006). The formation of
growing axons is accompanied by an increase in expression
of the growth cone protein, GAP-43 (Meiri et al. 1986): in
SH-SY5Y cells, differentiating factors, such as RA and PMA
have been shown to stimulate the expression of GAP-43
(Feng and Porter 1999). The anti-apoptotic protein Bcl-2 is
also up-regulated following differentiation of SH-SY5Y cells
(Feng and Porter 1999; Raguenez et al. 1999). In this study,
we have shown that PACAP treatment causes a clear up-
regulation of GAP-43 and Bcl-2 in SH-SY5Y cells, over the
Fig. 7 Involvement of Epac. (a) Western blot analysis of whole cell
extracts was carried out using antibodies speciﬁc for ERK, pERK and
p-p38 MAP kinase. The cells were maintained in low serum medium
for 24 h and stimulated with the indicated factors for 15 min
C = control, p = 100 nmol/L PACAP-38, F = 10 lmol/L forskolin and
CPT-cAMP = 100 lmol/L 8-CPT-Me-cAMP. (b) Western blot analysis
of whole cell extracts was carried out using antibodies speciﬁc for ERK
and pERK. Cells were stimulated for up to 2 h with 100 lmol/L 8-CPT-
Me-cAMP. The increase in phosphorylation levels was determined by
densitometry as described in Materials and methods and is graphically
represented in the lower section of the ﬁgure. Standard error bars are
shown. (c) Cells were maintained in low serum medium for 24 h then
stimulated with 100 lmol/L 8-CPT-Me-cAMP or with 100 nmol/L PA-
CAP-38 for 4 days. Control cells were kept in low serum medium
alone. The fold increase in neurite-bearing cells was determined as
described in the Materials and methods. Standard error bars are
shown (n = 3) and ANOVA analysis was carried out to identify sig-
niﬁcant differences between treatments (***p < 0.001). (e) Western
blot analysis of whole cell extracts using antibodies speciﬁc for Bcl-2
and GAP-43 was carried out. Protein loading was determined using an
antibody speciﬁc for GAPDH. Cells were treated for 4 days in low
serum medium alone (Control) or treated with 100 lmol/L 8-CPT-Me-
cAMP (CPT-cAMP) or with 100 nmol/L PACAP-38 (PACAP). Each
blot is representative of three independent experiments.
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(Fig. 1c). PACAP is known to regulate the formation of both
noradrenergic and cholinergic neurons during development
(May and Braas 1995; Braas and May 1996; Yuhara et al.
2003). Here we have shown that PACAP increases expres-
sion of the cholinergic marker ChAT, yet has little effect on
the high basal expression of the noradrenergic marker, TH
(Fig. 1c). PACAP therefore causes a switch from a norad-
renergic to a mixed noradrenergic and cholinergic phenotype.
These data show that PACAP is able to differentiate
SH-SY5Y cells into a more neuronal phenotype, with the
concomitant up-regulation of some well-characterized pro-
teins involved in neuritogenesis and cell survival.
We have shown previously that the PAC1 receptor is
primarily responsible for PACAP-elicited cAMP production
in SH-SY5Y cells (Lutz et al. 2006). In this study, the use of
the PAC1 receptor antagonist, PACAP6-38, in combination
with the VPAC2 receptor-speciﬁc agonist, Ro 25-1553 has
conﬁrmed that the observed effects of PACAP on differen-
tiation of SH-SY5Y cells are mediated by the PAC1 receptor
(Fig. 2). Treatment of the cells with the AC inhibitor, DDA,
and AC activator, forskolin, allowed us to determine that, as
anticipated, cAMP is the primary mediator of PACAP-
induced differentiation, inﬂuencing both neuritogenesis and
the expression of both Bcl-2 and GAP-43 (Fig. 3).
It has been shown previously that neurite extensions are
induced in SH-SY5Y cells by a cell permeable cAMP
analogue, dibutyryl cAMP (db-cAMP) (Sa ´nchez et al. 2004).
However, there are important differences between our
observations and those of the previous study regarding the
involvement of PKA, ERK, and p38 MAP kinase in this
process. Our study shows the strong activation of ERK and
p38 MAP kinase following treatment with PACAP-38 and
that this activation is dependent on AC activation. cAMP-
mediated activation of ERK has been shown to be PKA-
independent previously (Hashimoto et al. 2003), similarly, in
this study, activation of ERK and p38 MAP kinase was not
prevented by the PKA inhibitor, H89, or siRNA-mediated
knock-down of PKAc expression. Furthermore, neurito-
genesis was also observed to be cAMP-dependent but PKA-
independent (Fig. 4b and c). Well-characterized inhibitors
of ERK activation (PD98059) and p38 MAP kinase
(SB203580) provided evidence that both ERK and p38
MAP kinase contribute to the differentiation of SH-SY5Y
cells (Fig. 6a).
In the report by Sa ´nchez et al. (2004) db-cAMP-induced
neuritogenesis in SH-SY5Y cells involved a PKA-dependent
but ERK- and p38 MAP kinase-independent mechanism.
One explanation for the observed differences in results
between the current study and that of Sa ´nchez et al. is the
differing cell culturing conditions used during the differen-
tiation treatments, most notably the presence (this study) or
absence of serum (Sa ´nchez et al. 2004). It has been shown
that culturing neuroblastoma cells, including SH-SY5Y cells,
in serum-free medium induces neuritogenesis, even without
the addition of differentiating agents (Alleaume et al. 2004;
He ´raud et al. 2004; Buttiglione et al. 2007). The effect of
culturing SH-SY5Y cells in the serum-free medium without
db-cAMP was not reported by Sa ´nchez et al. (2004).
However, this is not likely to be the only contributing factor.
It has been reported that culturing SH-SY5Y cells in medium
containing low levels of serum (1% or less) promotes
neuritogenesis (Buttiglione et al. 2007). During the 4 day
time course used in our study, we did not observe a change in
the number of neurite-bearing cells when SH-SY5Y cells
were maintained in low serum medium (containing 0.2%
FBS). However, we deliberately used low passage cells (£20)
in our study as we observed that these did not spontaneously
differentiate when moved into the low serum medium,
whereas cells at higher passage numbers did (Monaghan and
Lutz, unpublished observations). This suggests that SH-
SY5Y cells may have regulatory mechanisms controlling
differentiation processes that are lost at higher cell passage
numbers, and that this should be considered when comparing
results from different studies.
It seems likely that the different means of elevating
intracellular cAMP levels that were used in the current study
compared to the previous study (agonist-stimulated GPCR-
mediated AC activation versus non-hydrolysable cAMP
analogue) was a major determinant on which mechanism
transduced the signal. It is generally agreed that cAMP-
mediated signaling is very complex and from the large
number of different reports, it seems possible that there is
more than one cAMP-activated transduction pathway that
will lead to neuritogenesis [see review by Dumaz and Marais
(2005)]. It is becoming increasingly evident that compart-
mentalization and the oscillatory pattern of intracellular
cAMP levels encode important information that is involved
in determining cellular effects (Rich et al. 2001; Zaccolo and
Pozzan 2003). Certainly, the neurite-guiding effect of
PACAP has been attributed to this (Guirland et al. 2003).
Indeed, when global cellular levels of cAMP were raised, this
was blocked. Furthermore, the cAMP signal is often
integrated with that of other signals, particularly Ca
2+, that
also regulate the activity of ACs and phosphodiesterases
(Zaccolo and Pozzan 2003). The PAC1 receptor can also
couple to the activation of phospholipase C and phospholi-
pase D in addition to AC activation (McCulloch et al. 2001;
Lutz et al. 2006), and the activation of these additional
pathways may modify the cAMP signal and/or the resulting
cellular effects evoked by PACAP. We are currently inves-
tigating this possibility. Maintaining cells for a long period of
time in medium containing a constant amount of a stable
cAMP analogue such as db-cAMP bypasses the GPCR/Gs/
AC regulatory control mechanisms. Furthermore, the possi-
ble long-term global increase in intracellular cAMP levels
may actually alter, or even prevent, the activation of
pathways that mediate a more compartmentalized cAMP
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tion of AC and presumably the subsequent regulation of the
signal through the activation of phosphodiesterases, protein
kinases and phosphatases that may be tethered or recruited
into nearby signaling complexes. The role of cAMP com-
partmentalization in neuronal differentiation remains to be
determined.
It is clear from studies of rat PC12 and related phaeo-
chromocytoma cell lines that there are certain parallels in the
mechanisms mediating the neurotrophic actions of PACAP
on these cells [see review by Ravni et al. (2006)] and those
which we have observed in SH-SY5Y cells. A role for Epac
in the cAMP-mediated differentiation of neuronal cells has
recently been described by Kiermayer et al. (2005), whose
study in PC12 cells described a cAMP-mediated, PKA-
independent activation of Epac causing a sustained activation
of ERK activity resulting in the differentiation of neuronal
cells. Shi et al. (2006) described distinct Epac/Rit/p38 and
Epac/Rap/ERK pathways contributing to PACAP-38-stimu-
lated neuritogenesis in another rat phaeochromocytoma cell
line, PC6 cells. However, in the human cells, the speciﬁc
activator of Epac, 8-CPT-Me-cAMP, caused a sustained
activation of ERK, a clear increase in GAP-43 expression
and a modest increase in neuritogenesis without inﬂuencing
p38 MAP kinase activation (Fig. 7). PACAP-38 stimulated
p38 MAP kinase through an AC-dependent and PKA-
independent mechanism that does not appear to be Epac-
mediated. The PKA-dependent activation of p38 MAP
kinase has been described (Delghandi et al. 2005), in this
case, however, PKA inhibition does not inﬂuence p38 MAP
kinase phosphorylation or neuritogenesis. However, CREB
phosphorylation and Bcl-2 expression are sensitive to
Fig. 8 Proposed model for the cAMP-dependent signaling events
involved in the neurotrophic actions of PACAP-38 on SH-SY5Y cells.
PACAP-38 binding to the PAC1 receptor, which couples to the acti-
vation of AC, evokes an increase in the intracellular levels of cAMP
(Lutz et al. 2006). This in turn leads to the activation of PKA-depen-
dent and PKA-independent mechanisms that are involved in the
induction of expression of neuronal proteins and in neuritogenesis,
respectively. The PKA-dependent mechanism involves PKA phos-
phorylation of the transcription factor CREB, initiating its activation and
translocation to the nucleus where it may be involved in the up-regu-
lated expression of proteins involved in neuronal differentiation,
including Bcl-2. The PKA-independent mechanisms involve activation
of MEK and ERK as well as p38 MAP kinase that are required for
neuritogenesis. The MEK/ERK activation possibly occurs through one
or a combination of different mechanisms. The neuronal MAP kinase
signaling cascade involves B-Raf as the ﬁrst component (Dugan et al.
1999) and it has been shown that the 95 kDa B-Raf kinase is ex-
pressed in SH-SY5Y cells (Stephens et al. 1992). However, it is still
unclear how cAMP activates B-Raf (Dumaz and Marais 2005). This
may occur through activation of the cAMP-dependent Rap 1 GEF,
Epac, or through another mechanism that may be potentiated by Epac
(Lin et al. 2003) but may or may not involve Rap1 (Dumaz and Marais
2005). An additional possibility is the cAMP-mediated activation of
PP2A (Feschenko et al. 2002) may directly induce B-Raf activation
(Strack 2002). Activated ERK is required for neuritogenesis as well as
being involved in the up-regulated expression of GAP-43, possibly
through translocation to the nucleus. cAMP mediates the activation of
p38 MAP kinase through a non-canonical pathway that may be similar
to that observed in Th2 cells (Chen et al. 2000) and in cardiac ﬁbro-
blasts (Yin et al. 2006), and which also may involve PP2A (Boudreau
et al. 2004). Activated p38 MAP kinase in turn is involved in the in-
creased expression of Bcl-2, possibly through phosphorylating CREB
(Yin et al. 2006) and/or other factors, as well as in neuritogenesis. The
arrows indicate direct interactions, the dotted arrows translocation,
and the dot dash arrows the possibility of one or a number of inter-
mediary steps that have not been worked out.
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regulation by the coincident activation of these kinases. The
activation of p38 MAP kinase is therefore cAMP-dependent
but Epac- and PKA-independent (a non-canonical pathway
recently described in Th2 cells (Chen et al. 2000) and mouse
cardiac ﬁbroblasts (Yin et al. 2006)). These data therefore
indicate that the PKA-independent, Epac-mediated activation
of ERK and cAMP-dependent, Epac-independent activation
of p38 MAP kinase pathways takes place in response to
PACAP-38 treatment and that both these pathways contribute
to PACAP-38-stimulated neuritogenesis in human neuro-
blastoma cells. Interestingly, the cAMP-dependent but PKA-
independent mechanism involved in the activation of ERK in
PC12 cells has not been entirely elucidated and there is the
distinct possibility that there may be additional novel cAMP-
regulated components involved in this (Gerdin and Eiden
2007) as appears to be the case in SH-SY5Y cells. One
possibility that we are investigating is the cAMP-mediated
activation of protein phosphatase 2A (Feschenko et al. 2002)
may induce B-Raf activation (Strack 2002) as well as p38
MAP kinase activation (Boudreau et al. 2004). A proposed
model of the signaling pathways involved in mediating the
neurotrophic actions of PACAP in SH-SY5Y cells is shown
in Fig. 8.
In summary, we have shown that PACAP-38-mediated
differentiation of SH-SY5Y cells is cAMP-dependent and
involves both PKA-dependent and PKA-independent mech-
anisms. The increase in cAMP levels led to phosphorylation
of ERK, p38 MAP kinase and JNK via a PKA-independent
mechanism. Activation of AC, ERK and p38 MAP kinase
were shown to be essential to fully differentiate SH-SY5Y
cells with PACAP. The cAMP-dependent guanine nucleotide
exchange factor, Epac, was implicated in the activation of
ERK and the resultant neuritogenesis. These results provide
further evidence of the neurotrophic actions of PACAP and
provide insight into how PACAP may function during
neuronal development and regeneration, highlighting the
importance of cAMP, Epac, ERK, and p38 MAP kinase in
these processes.
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